Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
Recruiting
Observational Study
Lung Cancer
Neoadjuvant Therapy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 400 (estimated)
- Sponsor
- Shanghai Chest Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational, retrospective, multicenter cohort study is to evaluate the surgical and oncologic outcomes of sleeve lobectomy performed via minimally invasive (RATS/VATS) or open thoracotomy approaches in patients with non-small cell lung cancer (NSCLC) who have undergone neoadjuvant therapy, including chemotherapy, immunotherapy, or combination regimens. The main questions this s…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years
* Histologically confirmed NSCLC
* Undergoing sleeve lobectomy with curative intent
* Receipt of neoadjuvant therapy (chemotherapy, immunotherapy, target therapy, etc.)
* Surgical approach: either minimally invasive (VATS or RATS) or open thoracotomy
* Availabil…
Contacts